Nima Farzan, Kinnate CEO
Kinase inhibitor specialist Kinnate launches Shanghai subsidiary with $35M to market its programs in China
A little more than five months after going public with a $276 million IPO, Kinnate Biopharma is back raising money — this time for a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
